Endocyte and Nihon Medi-Physics to develop companion imaging diagnostic
WEST LAFAYETTE, Ind.—Biopharmaceutical company Endocyte Inc. and Nihon Medi-Physics have established a license and commercialization agreement for the development and commercialization of the companion imaging diagnostic etarfolatide for cancer indications in Japan. Endocyte will receive an initial upfront payment and is eligible for development and regulatory milestones and royalties on sales of the product in Japan. The companies will seek approval for using etarfolatide to identify patients most likely to respond to vintafolida.
"NMP is committed to improving diagnosis of diseases with nuclear medicine procedures, and we are looking forward to collaborating with Endocyte, the leader in the small-molecule drug conjugate and companion imaging diagnostic space. This relationship will benefit patients and further strengthen NMP 's commercial leadership position in SPECT imaging in Japan," Yutaka Takeuchi, president of NMP, said in a press release.